In fact, EGFR-mutated NSCLC tumors highly express EREG [48,51,82], and treatment with EGFR-TKIs displayed limited antitumor activity against EREG-overexpressing lung tumors with EGFR mutations in a murine model [82]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.